Key points are not available for this paper at this time.
iraglutide is a long-acting human glucagon-like peptide-1 (GLP-1) analog (1-4), and the current study was undertaken to evaluate efficacy and safety after 14 weeks' treatment with liraglutide in patients with type 2 diabetes.
Vilsbøll et al. (Fri,) studied this question.